The Next Electricity Boom

Demand for electricity is a constant. Like Archimedes’ number pi, consumption has hardly changed since 2000. In the US, it stands at around 4,000 TWh (terawatt hours), in the EU at 3,000 TWh and in Switzerland at around 60 TWh.

Technological advances in energy efficiency have kept electricity demand in check over the past 20 years. This has enabled a remarkably smooth transition from coal-fired power to renewable energies. In Germany, the share of renewable energies in the electricity mix has risen from 3% in 2003 to 65% in the first half of 2025. This would have been considered almost impossible at the time, and the seemingly inevitable system crash has not materialised.

Today, remarkable things are happening in the electricity sector. The constant, i.e. demand, is becoming an accelerator.

Prometheus, Hyperion and Stargate

Prometheus, in Greek mythology, is the bringer of fire. The Prometheus of the electricity industry is Meta’s data centre of the same name in the state of Ohio. From 2026, computer chips here will convert up to 1,000 MW (megawatts) of electricity into AI applications and a lot of heat. This will significantly fuel demand for electricity. These facilities run around the clock. To illustrate: 1,000 MW is equivalent to the output of a large nuclear power plant.

At Meta, will be followed Prometheus by the Hyperion project in Louisiana. Hyperion, something like the creator of light in mythology, is expected to require 5,000 MW of power by 2030. The whole project is to be developed at the speed of light. Time is of the essence. In Texas, too, the Stargate project is reaching for the stars. The list could go on and on. Models assume that a total of 89,000 MW will be required for AI applications by 2030. This corresponds to almost the entire output of the 94 nuclear power plants currently in operation in the USA.

Refrigerators, air conditioning systems and data centres

Refrigerators and air conditioning systems were responsible for the last electricity boom in the 1950s and 1960s. Data centres are playing a key role in the electricity boom that is just beginning. We expect electricity demand in the US to grow by 4-7% per year until 2030. These are unprecedented levels.

Next electricity boom in the USA. Source: PPT, Clean Grid Initiative and McKinsey. June 2025.

For the first time in 25 years, electricity demand is growing faster than supply. Neither the electricity market nor investors are prepared for this structural change.

Timeframes and costs

Large-scale projects in hydro, nuclear or gas power take a long time to complete. A new gas turbine will not be connected to the grid before 2030, and new nuclear power plants will not be operational until 2035 at the earliest. Existing gas turbines that are not yet operating at their maximum capacity can only contribute a small portion of electricity production. The majority of the electricity gap must be covered by renewable energy sources.

A shortfall in electricity is much more serious than with other energy sources, as electricity is extremely difficult to store.

Wind and solar power plants with battery storage can be implemented quickly. Contrary to the ‘energy-reactionary’ zeitgeist, most subsidies for renewable energies have survived the ‘One Big Beautiful Bill Act’. However, the speed of implementation is not the only advantage of renewable energies. They are also unrivalled in terms of cost.

Onshore wind power with 4 hours of battery storage can be implemented at 25-50 USD/MWh. Solar power with the same storage costs 35 to 75 USD/MWh. The comparable costs of a new gas-fired combined cycle power plant currently amount to 90-115 USD/MWh. In Iowa and Colorado, the new wind turbines operate at full capacity over 40% of the time and generate electricity at a cost of less than 30 USD/MWh. With storage technology and AI applications in demand management, a reliable electricity supply can be implemented very cost-effectively.

Timeframe and costs of new production facilities. Source: NextEra Energy, August 2025. CCGT: combined cycle gas turbine, SMR: small modular reactor.

Electricity prices will rise significantly. In North America, prices could well double. The price increase overseas will happen faster than in Europe. Demand dynamics are many times stronger. Europe will follow with a delay of two to three years. In Switzerland, too, we will feel the surge in demand from data centres in Volketswil, Rafz and Dielsdorf.

Renewable energies are underestimated and undervalued by the capital market. Even though nuclear energy is once again a hot topic, over 80% of new production capacity will come from renewable energies in the next 5-10 years. In 2024, the figure was as high as 94% in the USA. The capital market has not valued the growth plans of electricity producers, or has even discounted them in relation to investments. This undervaluation offers an attractive entry point today.

New market participants with high willingness to pay. Rising electricity prices always harbour political risks. However, today’s electricity boom is being paid for by financially strong companies such as Google, Meta and Amazon. Regulators are called upon to take the right steps. Then electricity costs for all market participants can be stabilised, if not reduced.
Structural growth in the electricity sector offers further lucrative opportunities for investors.

It will take some time for market participants to realise what this structural change means for investments in the electricity sector.

Andreas Schneller is a partner at de Pury Pictet Turrettini & Cie SA and responsible for the ENETIA funds. He is portfolio manager of the ENETIA Energy Infrastructure Fund.

He has managed the fund since 2003. Since 2006, he has been co-portfolio manager of the ENETIA Energy Transition Fund. Mr Schneller has many years of experience in the electricity industry (EIC Partners AG and ABB). He studied business administration in St. Gallen and completed his CEMS Master’s degree at NHH in Bergen (Norway). He is a CFA charterholder.

 

Focus on digital health – Generative AI (GenAI) is driving the next stage of growth

UNIVEST Vermögensverwaltung AI in Health Da Vinci

New technologies are conquering the healthcare industry and improving care while reducing its cost. This development is urgently needed since demographic changes such as the ageing of the world’s population require greater efficiency and cost-effectiveness in the healthcare sector.

What are the major challenges and opportunities in the field of digital health? How do we benefit from innovations, not only in the event of a medical emergency, but also as investors?

Digitalisation in the healthcare sector has already made great progress and significantly improved the quality of treatment. Analogue systems have been replaced by digital X-ray images, cloud-connected continual blood glucose monitoring sensors and electronic patient records. Consequently, an enormous amount of health data has been collected, which now serves as a training basis for the large generative AI models. This, in turn, is significantly accelerating innovation in the healthcare sector.

Investment in artificial intelligence (AI) and its successful implementation will determine who the future winners in the healthcare industry will be in the coming years. From an investor’s perspective, it is therefore worth investing in those healthcare companies that have already integrated GenAI into their business models. The companies that are successful in doing so will emerge as share price winners over time.

Why is GenAI so relevant for the healthcare sector?

The healthcare sector is marked by enormously complex problems, for example in drug development. Lengthy development times and high failure rates cause the cost of a new drug to skyrocket into the billions.

GenAI technology can optimise the use of existing data from studies, research, development and patient data. This will not only allow drugs to be developed faster and in a more targeted manner in the future, but will also reduce the risks involved in development. New drug candidates can be identified more quickly, selected more successfully, optimised digitally and tested faster in laboratory experiments. This, again, generates large amounts of new data of the highest quality and new findings. The result is a ‘flywheel effect’, also for the share prices of pharmaceutical and biotech companies that successfully invest in GenAI.

AI against system inefficiencies

Another promising field of application for GenAI is the healthcare service sector, where there are massive system inefficiencies. One major beneficiary is the field of medical technology. The optimisation of methods of treatment significantly improves the quality of the treatment itself. For example, GenAI is not only used in diagnostic imaging, but also in AI-guided ultrasound examinations, sensor-based continuous blood glucose monitoring, surgical robotics and the early detection of heart failure and cancer. As a result, these ‘blockbuster markets’ are experiencing significant double-digit growth with the potential to double.

Assisted operations

Thanks to the latest generation of da Vinci 5 (dV5) surgical robots from Intuitive Surgical, patients and surgeons are already benefiting from GenAI technologies. Just as a Tesla can recognise pedestrians, cars and lorries in the vicinity of the route, dV5 automatically recognises the various vascular structures (coloured in the image on the left). dV5 can make suggestions for the next surgical step in accordance with clinical guidelines, monitor the operation and collect and ultimately evaluate all the data. As can be seen in the image on the right, statements can be made about the surgeon’s level of training and individual training units can be defined. Overall, this prevents complications during surgery, which increases the quality of treatment and reduces overall treatment costs.

While the surgeon controls the dV5 surgical robot entirely herself – unlike in the Tesla example, the robot does not carry out surgical steps autonomously – there are already surgical systems such as Hydros from Procept BioRobotics that can carry out surgical planning and the removal of excess prostate tissue independently. The surgeon exclusively monitors the entire process: she verifies the surgical plan generated by the GenAI, improves it if necessary, monitors the automatically performed tissue removal and intervenes if something unforeseen should occur.

How can you profit as an investor?

The Bellevue Digital Health (and Medtech & Services and AI Health) Fund invests in this megatrend. From a fundamental perspective, digital health companies are on a stable, above-average growth trajectory that is likely to continue unchanged in 2024. The approval and market launch of relevant new products will ensure continued high sales growth. Examples include the aforementioned Stelo and G7 blood glucose sensors from Dexcom, the new robot-based da Vinci 5 surgical system from Intuitive Surgical and Hydros from Procept BioRobotics.

We expect a tailwind for our investment solution for the remainder of 2024 and all of 2025. Factors such as the first US interest rate cuts due to a slowdown in the US economy (growth stocks usually benefit more than average), attractive valuation levels (sales multiples close to historical lows), expected acceleration of M&A and IPO activity, repositioning of investors from the high-flyers of recent months into high-quality stocks speak in favour of an investment in the Bellevue Digital Health (Lux) Fund.

 

Stefan Blum is Senior Portfolio Manager of Bellevue Medtech & Services (Lux), Bellevue Digital Health (Lux) and Bellevue AI Health (Lux) Funds.